Tsuzuki Wada Takuma, Yokota Kazuhiro, Okada Mariko, Ichimura Takaya, Ueno Takehito, Okumura Nobuhito, Osawa Iichiro, Inoue Kaiji, Akiyama Yuji, Nakazato Yoshihiko, Sasaki Atsushi, Yamamoto Toshimasa, Mimura Toshihide
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan.
Department of Neurology, Faculty of Medicine, Saitama Medical University, Japan.
Intern Med. 2025 Jul 1;64(13):2073-2079. doi: 10.2169/internalmedicine.4503-24. Epub 2024 Dec 26.
We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.
我们在此报告一名52岁女性，患有抗水通道蛋白4抗体阳性的视神经脊髓炎谱系障碍（NMOSD）和特发性多中心Castleman病（iMCD），她接受了托珠单抗（一种人源化抗人白细胞介素（IL）-6受体单克隆抗体）治疗并取得成功。这是首例NMOSD和iMCD共存病例的报告。IL-6参与了NMOSD和iMCD的发病机制，托珠单抗对这两种疾病均有效。通过用托珠单抗治疗该患者，iMCD所致的肺部病变得到改善，且NMOSD的神经症状未复发。
